Jun 23, 2026 05:20PM
Jun 23, 2026 05:20PM
Jun 15, 2026 03:45AM
Jun 10, 2026 06:30PM
May 19, 2026 03:05AM
Apr 28, 2026 03:05AM
Apr 14, 2026 03:05AM BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
Apr 7, 2026 03:05AM
Mar 30, 2026 03:05AM
Mar 24, 2026 05:10AM
Mar 17, 2026 03:05AM
Mar 17, 2026 03:05AM
Feb 26, 2026 07:00PM
Feb 17, 2026 03:05AM BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
Feb 5, 2026 03:05AM
Jan 26, 2026 03:05AM
Jan 21, 2026 03:05AM
Jan 19, 2026 03:05AM
Dec 17, 2025 03:05AM
Dec 9, 2025 03:05AM
Dec 1, 2025 03:05AM BioNxt signs agreement to acquire sublingual drug formulation IP
Dec 1, 2025 03:05AM
Nov 20, 2025 03:05AM
Nov 4, 2025 03:05AM
Oct 30, 2025 03:05AM
Oct 21, 2025 03:05AM
Oct 9, 2025 07:50PM
Oct 9, 2025 03:05AM BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
Oct 2, 2025 03:05AM
Sep 29, 2025 03:05AM
Sep 19, 2025 07:30PM
Sep 12, 2025 07:00PM
Sep 5, 2025 03:05AM
Aug 15, 2024 03:05AM
Jul 17, 2024 03:05AM BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
Jul 9, 2024 03:05AM

406,351 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All